CRM197 reverses paclitaxel resistance by inhibiting the NAC‐1/Gadd45 pathway in paclitaxel‐resistant ovarian cancer cells

Heparin‐binding epidermal growth factor‐like growth factor (HB‐EGF) is a new promising target for the treatment of ovarian cancer. Our previous study showed that cross‐reacting material 197 (CRM197), a specific HB‐EGF inhibitor, significantly reverses resistance against paclitaxel in paclitaxel‐resi...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Tang, Xiao‐han, Li, Hui, Zheng, Xiu‐shuang, Lu, Mei‐song, An, Yuan, Zhang, Xiao‐lei
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2019
Teme:
Cancer Prevention
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6797568/
https://ncbi.nlm.nih.gov/pubmed/31490008
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.2512
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items